retatrutide 2 week results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Effects of once-weekly subcutaneous retatrutide

In rough trial comparisons, Retatrutides TRIUMPH-1 data shows around 28.3% mean weight loss at 80 weeks on the 12 mg dose, with up to 30.3% at 104 weeks in a select extension population

GLP-1 agonists are available through prescription from SheMed Healthcare

Regardless of the cause, the pattern remains consistent: expect worse nausea initially, but know it typically resolves

For patients, this is potentially good news because this itch can be so bad that it disrupts sleep, causes extreme fatigue, and ruins quality of life, yet there are very few treatments for it

Frequently asked questions (FAQs) GLP-1 nausea can be a persistent side effect, or can go away less than an hour after eating

By purchasing, the customer acknowledges they are qualified to handle and use these materials and that Regentide shall not be held liable for any misuse